



A Pilot Study to Evaluate the Navigator Continuous Glucose Sensor in the Management of Type 1 Diabetes in Children Version 1.4 December 3, 2004

24	
25	
26	Coordinating Center
27 28	Jaeb Center for Health Research
29	Roy W. Beck, M.D., Ph.D. (Director)
30	Katrina J. Ruedy, M.S.P.H. (Assistant Director)
31	15310 Amberly Drive, Suite 350
32	Tampa, FL 33647
33	Phone (813) 975-8690
34	Fax (813) 903-8227
35	Email: <u>direcnet@jaeb.org</u>
36	
37	

38	Table of Contents	
39 40	1. Chapter 1: Introduction	1-1
41	1.1 Introduction and Rationale	
42	1.2 Background on the Navigator	
43	1.3 Synopsis of Study Protocol	
44 45	2. Chapter 2: Subject Eligibility and Enrollment	2-1
46	2.1 Study Population	
47	2.2 Eligibility and Exclusion Criteria	
48	2.2.1 Eligibility	
49	2.2.2 Exclusion	
50	2.3 Patient Enrollment and Baseline Data Collection	
51	2.3.1 Historical Information and Physical Exam	
52	2.3.2 Informed Consent	
53	2.3.2.1 Authorization Procedures	
54	2.3.2.2 Special Consent Issues	
55	2.3.3 Hemoglobin A1c Determination	
56	2.3.4 Questionnaire Completion	
57	2.3.5 Instructions for Home Procedures	
58		
59	3. Chapter 3: Inpatient CRC Admission	
60	3.1 Overview	
61	3.2 Navigator Management and Procedures	
62	3.2.1 Navigator Placement	
63	3.2.3 Sensor Failure	
64	3.3 Reference Glucose Measurements	
65	3.3.1 Volume of Blood Draws	
66	3.3.2 Quality Control Specimens	
67	3.4 Glucose Measurements with the Study Home Glucose Meter	
68	3.5 Blood Glucose Testing for Hypoglycemia	
69	3.6 Exercise Session	
70	3.7 Meal-Induced Hyperglycemia Test	
71	3.8 Diabetes Management	
72	3.9 Algorithms for Diabetes Management	
73	3.10 Daily Activities	
74	3.11 Diet	
75	3.12 Hospital Discharge	
76	5.12 Hospital Discharge	····· J-+
77	4. Chapter 4: Home Procedure and Diabetes Management	4-1
78	4.1 Home Glucose Monitor	
79	4.2 Frequency of Use of the Navigator	
80	4.3 Instructions for Use of the Navigator	
81	4.4 Downloading the Navigator	
82	4.5 Self-assessment using Software	
82 83	4.5 Sen-assessment using Software	
83 84	4.0 Algorithms for Diabetes Management Decisions	
85	5. Chapter 5: Follow-Up	5_1
86	5.1 Timing of Visits	
00	5.1 Thinng OF VISIO	

1148.2 Subject/Parent Reimbursement	87	5.2 Overview	5-1
89 5.4 Phone Calls to Subjects 5-1 90 6. Chapter 6:Questionnaires 6-1 91 6. Chapter 6:Questionnaires 6-1 92 6.1 PedsQL Diabetes Module 6-1 93 6.2 Diabetes Self-Management Profile (Treatment Adherence Questionnaire) 6-1 94 6.3 Continuous Glucose Monitor Satisfaction Scale 6-1 95 6.4 Insulin Dose Adjustment Guidelines Satisfaction Questionnaire 6-1 96 7. Chapter 7:Adverse Events 7-1 97 7. Definitions 7-1 98 7.1 Events To Be Reported 7-1 97 7. Definitions 7-1 97 7. Definitions 7-1 97 7. Stass and Discomforts 7-1 97 7.5 I Navigator 7-2 97 7.5 T Nervise Risks 7-2 97 7.5 I Navigator 7-2 97 7.5 Discretise Risks 7-2 96 7.5.4 IV Risks 7-2 97 7.5 Dest-breakfast Hyperglycemia 7-2 97 7.5 Dest-breakfast Hyperglycemia 7-2 97 <td< td=""><td>88</td><td>5.3 Continued use of the Navigator</td><td> 5-1</td></td<>	88	5.3 Continued use of the Navigator	5-1
90 6. Chapter 6:Questionnaires 6-1 91 6. Chapter 6:Questionnaires 6-1 92 6.1 PedxQL Diabetes Module 6-1 93 6.2 Diabetes Self-Management Profile (Treatment Adherence Questionnaire) 6-1 94 6.3 Continuous Glucose Monitor Satisfaction Scale 6-1 95 6.4 Insulin Dose Adjustment Guidelines Satisfaction Questionnaire 6-1 96 7. Chapter 7:Adverse Events 7-1 97 7. Chapter 7:Adverse Events 7-1 97 7.2 Definitions. 7-1 97 7.2 Disconting Requirements for Serious and/or Unexpected Adverse Events. 7-1 97 7.4 Data and Safety Monitoring Board 7-1 97 7.5 Risks and Discomforts. 7-1 90 7.5.1 Navigator. 7-1 91 7.5 Risks and Discomforts. 7-2 92 7.5 Risks and Discomforts. 7-2 93 7.5 Risks and Discomforts. 7-2 94 7.5.1 Navigator. 7-2 95 7.5.2 Fingerstick Blood Glucose Measurements. 7-2 96 7.5.4 IV Risks 7-2 97	89	-	
92 6. Î PedsQL Diabetes Module 6-1 93 6. 2 Diabetes Self-Management Profile (Treatment Adherence Questionnaire) 6-1 94 6.3 Continuous Glucose Monitor Satisfaction Scale 6-1 95 6.4 Insulin Dose Adjustment Guidelines Satisfaction Questionnaire 6-1 96 7. Chapter 7:Adverse Events 7-1 97 7. Chapter 7:Adverse Events 7-1 98 7.1 Events To Be Reported 7-1 99 7.2 Definitions. 7-1 100 7.3 Reporting Requirements for Serious and/or Unexpected Adverse Events. 7-1 101 7.4 Data and Safety Monitoring Board 7-1 102 7.5 Risks and Discomforts. 7-2 103 7.5.1 Navigator. 7-1 104 7.5.2 Fingerstick Blood Glucose Measurements. 7-2 105 7.5.3 Psychosocial Questionnaires. 7-2 106 7.5.4 Ki of Hypoglycemia 7-2 107 7.5.5 Exercise Risks. 7-2 108 7.5.8 Blood Volume Requirements. 7-3 119 8. Chapter 8: Miscellancous Considerations in Follow Up 8-1 118 8. Chapter 9: Statis	90	5	
92 6. Î PedsQL Diabetes Module 6-1 93 6. 2 Diabetes Self-Management Profile (Treatment Adherence Questionnaire) 6-1 94 6.3 Continuous Glucose Monitor Satisfaction Scale 6-1 95 6.4 Insulin Dose Adjustment Guidelines Satisfaction Questionnaire 6-1 96 7. Chapter 7:Adverse Events 7-1 97 7. Chapter 7:Adverse Events 7-1 98 7.1 Events To Be Reported 7-1 99 7.2 Definitions. 7-1 100 7.3 Reporting Requirements for Serious and/or Unexpected Adverse Events. 7-1 101 7.4 Data and Safety Monitoring Board 7-1 102 7.5 Risks and Discomforts. 7-2 103 7.5.1 Navigator. 7-1 104 7.5.2 Fingerstick Blood Glucose Measurements. 7-2 105 7.5.3 Psychosocial Questionnaires. 7-2 106 7.5.4 Ki of Hypoglycemia 7-2 107 7.5.5 Exercise Risks. 7-2 108 7.5.8 Blood Volume Requirements. 7-3 119 8. Chapter 8: Miscellancous Considerations in Follow Up 8-1 118 8. Chapter 9: Statis	91	6. Chapter 6:Questionnaires	6-1
93 6.2 Diabetes Self-Management Profile (Treatment Adherence Questionnaire) 6-1 94 6.3 Continuous Glucose Monitor Satisfaction Scale 6-1 95 6.4 Insulin Dose Adjustment Guidelines Satisfaction Questionnaire 6-1 96 7. Chapter 7:Adverse Events 7-1 97 7. Chapter 7:Adverse Events 7-1 98 7.1 Events To Be Reported 7-1 99 7.2 Definitions 7-1 100 7.4 Reporting Requirements for Serious and/or Unexpected Adverse Events 7-1 101 7.4 Data and Safety Monitoring Board 7-1 102 7.5.1 Navigator. 7-1 103 7.5.1 Navigator. 7-2 104 7.5.2 Fingerstick Blood Glucose Measurements. 7-2 105 7.5.3 Psychosocial Questionnaires. 7-2 106 7.5.4 Risk of Hypoglycemia 7-2 107 7.5.5 Exercise Risks. 7-2 108 7.5.6 Risk of Hypoglycemia 7-2 109 7.5.8 Blood Volume Requirements. 7-3 111 8.1 Benefits. 8-1 112 8. Chapter 8: Miscellaneous Considerations in Follow Up 8-	92		
94 6.3 Continuous Glucose Monitor Satisfaction Scale. 6-1 95 6.4 Insulin Dose Adjustment Guidelines Satisfaction Questionnaire 6-1 96 7. Chapter 7:Adverse Events 7-1 97 7. Levents To Be Reported. 7-1 99 7.2 Definitions. 7-1 90 7.3 Reporting Requirements for Serious and/or Unexpected Adverse Events. 7-1 100 7.3 Reporting Requirements for Serious and/or Unexpected Adverse Events. 7-1 101 7.4 Data and Safety Monitoring Board 7-1 102 7.5 Risks and Discomforts. 7-1 103 7.5.1 Navigator. 7-1 104 7.5.2 Fingerstick Blood Glucose Measurements. 7-2 105 7.5.3 Psychosocial Questionnaires. 7-2 106 7.5.4 IV Risks. 7-2 107 7.5.5 Exercise Risks. 7-2 108 7.5.7 Post-breakfast Hyperglycemia 7-2 109 7.5.7 Post-breakfast Hyperglycemia follow Up 8-1 118 8.1 Benefits. 8-1 118 8.2 Subject Windrawal 8-1 118 8.2 Subject Windrawal 8-1	93		
95 6.4 Insulin Dose Adjustment Guidelines Satisfaction Questionnaire 6-1 96 7. Chapter 7:Adverse Events 71 97 7. Chapter 7:Adverse Events 7-1 98 7.1 Events To Be Reported. 7-1 99 7.2 Definitions. 7-1 91 7.2 Beporting Requirements for Serious and/or Unexpected Adverse Events. 7-1 101 7.4 Data and Safety Monitoring Board 7-1 102 7.5 Risks and Discomforts. 7-1 103 7.5.1 Navigator. 7-1 104 7.5.2 Fingerstick Blood Glucose Measurements. 7-2 105 7.5.3 Psychosocial Questionnaires. 7-2 106 7.5.4 IV Risks 7-2 107 7.5.6 Exercise Risks. 7-2 108 7.5.6 Risk of Hypoglycemia 7-2 109 7.5.7 Post-breakfast Hyperglycemia 7-2 101 7.5.8 Riscellaneous Considerations in Follow Up 8-1 118 8.1 Benefits. 8-1 118 8.2 Subject/Parent Reimbursement 8-1 118 8.3 Subject Withdrawal 8-1 118 8.4 Confidentiali	94		
96 7. Chapter 7:Adverse Events 7-1 98 7.1 Events To Be Reported. 7-1 99 7.2 Definitions. 7-1 100 7.3 Reporting Requirements for Serious and/or Unexpected Adverse Events. 7-1 101 7.4 Data and Safety Monitoring Board 7-1 102 7.5 Risks and Discomforts. 7-1 103 7.5.1 Navigator. 7-1 104 7.5.2 Fingerstick Blood Glucose Measurements. 7-2 105 7.5.3 Psychosocial Questionnaires. 7-2 106 7.5.4 IV Risks 7-2 107 7.5.5 Exercise Risks. 7-2 108 7.5.6 Risk of Hypoglycemia 7-2 109 7.5.7 Post-breakfast Hyperglycemia 7-2 100 7.5.8 Blood Volume Requirements. 7-3 111 8. Chapter 8: Miscellaneous Considerations in Follow Up 8-1 113 8.1 Benefits. 8-1 114 8.2 Subject/Parent Reimbursement 8-1 115 8.3 Subject Withdrawal 8-1 116 8.4 Confidentiality. 8-1 117 9.2 Analysis Plan. 9-1	95		
98 7.1 Events To Be Reported	96		
98 7.1 Events To Be Reported	97	7. Chapter 7:Adverse Events	7-1
99 7.2 Definitions	98	-	
100 7.3 Reporting Requirements for Serious and/or Unexpected Adverse Events. 7-1 101 7.4 Data and Safety Monitoring Board 7-1 102 7.5 Risks and Discomforts. 7-1 103 7.5.1 Navigator. 7-1 104 7.5.2 Fingerstick Blood Glucose Measurements. 7-2 105 7.5.3 Psychosocial Questionnaires. 7-2 106 7.5.4 IV Risks 7-2 107 7.5.5 Exercise Risks. 7-2 108 7.5.6 Risk of Hypoglycemia 7-2 109 7.5.7 Post-breakfast Hyperglycemia 7-2 110 7.5.8 Blood Volume Requirements. 7-3 111 8. Chapter 8: Miscellaneous Considerations in Follow Up 8-1 113 8.1 Benefits. 8-1 114 8.2 Subject/Parent Reimbursement 8-1 115 8.3 Subject Withdrawal 8-1 116 8.4 Confidentiality 8-1 117 9.1 Sample Size 9-1 118 9. Chapter 9: Statistical Considerations 9-1 119 9.1 Sample Size 9-1 120 9.2.1 Assessment of the Feasibility of Usi	99	1	
101 7.4 Data and Safety Monitoring Board 7-1 102 7.5 Risks and Discomforts 7-1 103 7.5.1 Navigator. 7-1 104 7.5.2 Fingerstick Blood Glucose Measurements. 7-2 105 7.5.3 Psychosocial Questionnaires. 7-2 106 7.5.4 IV Risks 7-2 107 7.5.5 Exercise Risks. 7-2 108 7.5.6 Risk of Hypoglycemia 7-2 109 7.5.7 Post-breakfast Hyperglycemia 7-2 100 7.5.8 Blood Volume Requirements. 7-3 110 7.5.8 Blood Volume Requirements. 7-3 111 8. Chapter 8: Miscellaneous Considerations in Follow Up 8-1 112 8. Chapter 9: Statistical Considerations in Follow Up 8-1 113 8.1 Benefits. 8-1 114 8.2 Subject/Parent Reimbursement 8-1 115 8.3 Subject Withdrawal 8-1 116 8.4 Confidentiality 8-1 117 9.1 Sample Size 9-1 118 9. Chapter 9: Statistical Considerations 9-1 119 9.1 Sample Size 9-1 <	100		
102 7.5 Risks and Discomforts. 7-1 103 7.5.1 Navigator. 7-1 104 7.5.2 Fingerstick Blood Glucose Measurements. 7-2 105 7.5.3 Psychosocial Questionnaires. 7-2 106 7.5.4 IV Risks. 7-2 107 7.5.5 Exercise Risks. 7-2 109 7.5.6 Risk of Hypoglycemia 7-2 109 7.5.7 Post-breakfast Hyperglycemia 7-2 110 7.5.8 Blood Volume Requirements. 7-3 111 8. Chapter 8: Miscellaneous Considerations in Follow Up 8-1 113 8.1 Benefits. 8-1 114 8.2 Subject/Parent Reimbursement 8-1 115 8.3 Subject Withdrawal. 8-1 116 8.4 Confidentiality 8-1 117 9.1 Sample Size 9-1 118 9.1 Sample Size 9-1 119 9.1 Sample Size 9-1 120 9.2.1 Assessment of the Feasibility of Using the Navigator on a daily basis 9-1 121 9.2.2 Development and testing of Algorithms 9-1 122 9.2.4 Ipifference Measures 9-1	101		
103 7.5.1 Navigator	102		
104 7.5.2 Fingerstick Blood Glucose Measurements 7-2 105 7.5.3 Psychosocial Questionnaires 7-2 106 7.5.4 IV Risks 7-2 107 7.5.5 Exercise Risks 7-2 108 7.5.6 Risk of Hypoglycemia 7-2 109 7.5.7 Post-breakfast Hyperglycemia 7-2 100 7.5.8 Blood Volume Requirements 7-3 111 8.1 Benefits 8-1 112 8. Chapter 8: Miscellaneous Considerations in Follow Up 8-1 113 8.1 Benefits 8-1 114 8.2 Subject/Parent Reimbursement 8-1 115 8.3 Subject Withdrawal 8-1 116 8.4 Confidentiality 8-1 117 9.1 Chapter 9: Statistical Considerations 9-1 118 9.2 Analysis Plan 9-1 119 9.1 Assessment of the Feasibility of Using the Navigator on a daily basis 9-1 112 9.2.1 Assessment of the Statigator 9-1 123 9.2.3 Questionnaires 9-1 124 9.2.4.1 Difference Measures 9-1 125 9.2.4.3 Detection of Hypoglycemia			
1057.5.3 Psychosocial Questionnaires7-21067.5.4 IV Risks7-21077.5.5 Exercise Risks7-21087.5.6 Risk of Hypoglycemia7-21097.5.7 Post-breakfast Hyperglycemia7-21007.5.8 Blood Volume Requirements7-31118. Chapter 8: Miscellaneous Considerations in Follow Up8-11138.1 Benefits8-11148.2 Subject/Parent Reimbursement8-11158.3 Subject Withdrawal8-11168.4 Confidentiality8-11179. Chapter 9: Statistical Considerations9-11189. Chapter 9: Statistical Considerations9-11209.2 Analysis Plan9-11219.2.1 Assessment of the Feasibility of Using the Navigator on a daily basis9-11229.2.2 Development and testing of Algorithms9-11239.2.3 Questionnaires9-11249.2.4 Inpatient Accuracy of the Navigator9-11259.2.4.1 Difference Measures9-11269.2.4.2 Precision9-21279.2.4.3 Detection of Hypoglycemia9-21289.2.4.4 Detection of Hypoglycemia9-21299.2.4.5 Assessment of Navigator Function during Exercise9-21319.2.5 Outpatient Accuracy of the Navigator Function Post-Breakfast9-21319.2.5 Outpatient Accuracy of the Navigator9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory		-	
106 7.5.4 IV Risks 7-2 107 7.5.5 Exercise Risks 7-2 108 7.5.6 Risk of Hypoglycemia 7-2 109 7.5.7 Post-breakfast Hyperglycemia 7-2 100 7.5.8 Blood Volume Requirements 7-3 111 8. Chapter 8: Miscellaneous Considerations in Follow Up 8-1 113 8.1 Benefits 8-1 114 8.2 Subject/Parent Reimbursement 8-1 115 8.3 Subject Withdrawal 8-1 116 8.4 Confidentiality 8-1 117 9. Chapter 9: Statistical Considerations 9-1 119 9.1 Sample Size 9-1 120 9.2 Analysis Plan 9-1 121 9.2.1 Assessment of the Feasibility of Using the Navigator on a daily basis 9-1 122 9.2.2 Development and testing of Algorithms 9-1 123 9.2.3 Questionnaires 9-1 124 9.2.4.1 Difference Measures 9-1 125 9.2.4.1 Difference Measures 9-1 126 9.2.4.2 Precision 9-2 127 9.2.4.3 Detection of Hypoglycemia 9-2 <		6	
1077.5.5 Exercise Risks7-21087.5.6 Risk of Hypoglycemia7-21097.5.7 Post-breakfast Hyperglycemia7-21107.5.8 Blood Volume Requirements7-31118. Chapter 8: Miscellaneous Considerations in Follow Up8-11128. Chapter 8: Miscellaneous Considerations in Follow Up8-11138.1 Benefits8-11148.2 Subject/Parent Reimbursement8-11158.3 Subject Withdrawal8-11168.4 Confidentiality8-11179.1 Sample Size9-11199.1 Sample Size9-11209.2.1 Assessment of the Feasibility of Using the Navigator on a daily basis9-11219.2.2 Development and testing of Algorithms9-11229.2.3 Questionnaires9-11239.2.4.1 Difference Measures9-11249.2.4.1 Difference Measures9-11259.2.4.2 Precision9-21269.2.4.3 Detection of Hypoglycemia9-21279.2.4.3 Detection of Hypoglycemia9-21289.2.4.4 Detection of Hypoglycemia9-21299.2.4.5 Assessment of Navigator Function during Exercise9-21319.2.5 Outpatient Accuracy of the Navigator Innction during Exercise9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and4143Algorithms on A1c and Frequency of Hypoglycemia9-3 <tr< td=""><td></td><td></td><td></td></tr<>			
108 7.5.6 Risk of Hypoglycemia 7-2 109 7.5.7 Post-breakfast Hyperglycemia 7-2 110 7.5.8 Blood Volume Requirements. 7-3 111 8. Chapter 8: Miscellaneous Considerations in Follow Up 8-1 113 8.1 Benefits. 8-1 114 8.2 Subject/Parent Reimbursement 8-1 115 8.3 Subject Withdrawal 8-1 116 8.4 Confidentiality 8-1 117 9. Chapter 9: Statistical Considerations 9-1 118 9. Chapter 9: Statistical Considerations 9-1 119 9.1 Sample Size 9-1 120 9.2.1 Assessment of the Feasibility of Using the Navigator on a daily basis 9-1 121 9.2.1 Development and testing of Algorithms 9-1 122 9.2.2 Development and testing of Algorithms 9-1 123 9.2.4 Inpatient Accuracy of the Navigator 9-1 124 9.2.4.1 Difference Measures 9-1 125 9.2.4.2 Precision 9-2 126 9.2.4.2 Precision 9-2 127 9.2.4.5 Assessment of Navigator Function during Exercise 9-2			
1097.5.7 Post-breakfast Hyperglycemia7-21107.5.8 Blood Volume Requirements7-31118. Chapter 8: Miscellaneous Considerations in Follow Up8-11138.1 Benefits8-11148.2 Subject/Parent Reimbursement8-11158.3 Subject Withdrawal8-11168.4 Confidentiality8-11179. Chapter 9: Statistical Considerations9-11199.1 Sample Size9-11209.2 Analysis Plan9-11219.2.1 Assessment of the Feasibility of Using the Navigator on a daily basis9-11229.2.2 Development and testing of Algorithms9-11239.2.3 Questionnaires9-11249.2.4 Inpatient Accuracy of the Navigator9-11259.2.4.1 Difference Measures9-11269.2.4.2 Precision9-21279.2.4.3 Detection of Hypoglycemia9-21289.2.4.4 Detection of Hypoglycemia9-21299.2.4.5 Assessment of Navigator Function during Exercise9-21309.2.4.6 Assessment of Navigator Function Post-Breakfast9-21319.2.5 Outpatient Accuracy of the Navigator9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and31359.2.8 Severe Hypoglycemia9-3			
110 7.5.8 Blood Volume Requirements			
111 8. Chapter 8: Miscellaneous Considerations in Follow Up 8-1 113 8.1 Benefits 8-1 114 8.2 Subject/Parent Reimbursement 8-1 115 8.3 Subject Withdrawal 8-1 116 8.4 Confidentiality 8-1 117 9. Chapter 9: Statistical Considerations 9-1 119 9.1 Sample Size 9-1 120 9.2 Analysis Plan 9-1 121 9.2.1 Assessment of the Feasibility of Using the Navigator on a daily basis 9-1 122 9.2.2 Development and testing of Algorithms 9-1 123 9.2.3 Questionnaires 9-1 124 9.2.4.1 Difference Measures 9-1 125 9.2.4.2 Precision 9-2 126 9.2.4.2 Precision 9-2 127 9.2.4.3 Detection of Hypoglycemia 9-2 128 9.2.4.4 Detection of Hypoglycemia 9-2 129 9.2.4.5 Assessment of Navigator Function Post-Breakfast 9-2 129 9.2.4.6 Assessment of Navigator Function Post-Breakfast 9-2 131 9.2.5 Outpatient Accuracy of the Navigator 9-2 <td< td=""><td></td><td></td><td></td></td<>			
1128. Chapter 8: Miscellaneous Considerations in Follow Up8-11138.1 Benefits8-11148.2 Subject/Parent Reimbursement8-11158.3 Subject Withdrawal8-11168.4 Confidentiality8-11179. Chapter 9: Statistical Considerations9-11199.1 Sample Size9-11209.2 Analysis Plan9-11219.2.1 Assessment of the Feasibility of Using the Navigator on a daily basis9-11229.2.2 Development and testing of Algorithms9-11239.2.3 Questionnaires9-11249.2.4 Inpatient Accuracy of the Navigator9-11259.2.4.1 Difference Measures9-11269.2.4.2 Precision9-21279.2.4.3 Detection of Hypoglycemia9-21289.2.4.4 Detection of Hypoglycemia9-21299.2.4.5 Assessment of Navigator Function during Exercise9-21319.2.5 Outpatient Accuracy of the Navigator Pusciton Post-Breakfast9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and Algorithms on A1c and Frequency of Hypoglycemia9-31359.2.8 Severe Hypoglycemia9-3	-	fiele Blood Volume Requirements	
1138.1 Benefits.8-11148.2 Subject/Parent Reimbursement8-11158.3 Subject Withdrawal.8-11168.4 Confidentiality.8-11179. Chapter 9: Statistical Considerations9-11199.1 Sample Size9-11209.2 Analysis Plan9-11219.2.1 Assessment of the Feasibility of Using the Navigator on a daily basis9-11229.2.2 Development and testing of Algorithms9-11239.2.3 Questionnaires.9-11249.2.4 Inpatient Accuracy of the Navigator9-11259.2.4.1 Difference Measures9-11269.2.4.2 Precision.9-21279.2.4.3 Detection of Hypoglycemia9-21289.2.4.4 Detection of Hypoglycemia9-21309.2.4.6 Assessment of Navigator Function during Exercise9-21319.2.5 Outpatient Accuracy of the Navigator9-21319.2.5 Outpatient Accuracy of the Navigator9-21339.2.7 Exploratory Assessment of Navigator Function Post-Breakfast9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and9-31359.2.8 Severe Hypoglycemia9-3		8. Chapter 8: Miscellaneous Considerations in Follow Up	
1148.2 Subject/Parent Reimbursement8-11158.3 Subject Withdrawal8-11168.4 Confidentiality8-11179. Chapter 9: Statistical Considerations9-11189. Chapter 9: Statistical Considerations9-11199.1 Sample Size9-11209.2 Analysis Plan9-11219.2.1 Assessment of the Feasibility of Using the Navigator on a daily basis9-11229.2.2 Development and testing of Algorithms9-11239.2.3 Questionnaires9-11249.2.4 Inpatient Accuracy of the Navigator9-11259.2.4.1 Difference Measures9-11269.2.4.2 Precision9-21279.2.4.3 Detection of Hypoglycemia9-21289.2.4.4 Detection of Hypoglycemia9-21299.2.4.5 Assessment of Navigator Function during Exercise9-21319.2.5 Outpatient Accuracy of the Navigator9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and1341359.2.8 Severe Hypoglycemia9-3	113		
1158.3 Subject Withdrawal	114		
1168.4 Confidentiality8-11179. Chapter 9: Statistical Considerations9-11199.1 Sample Size9-11209.2 Analysis Plan9-11219.2.1 Assessment of the Feasibility of Using the Navigator on a daily basis9-11229.2.2 Development and testing of Algorithms9-11239.2.3 Questionnaires9-11249.2.4 Inpatient Accuracy of the Navigator9-11259.2.4.1 Difference Measures9-11269.2.4.2 Precision9-21279.2.4.3 Detection of Hypoglycemia9-21289.2.4.4 Detection of Hyperglycemia9-21299.2.4.5 Assessment of Navigator Function during Exercise9-21309.2.4.6 Assessment of Navigator Function Post-Breakfast9-21319.2.5 Outpatient Accuracy of the Navigator9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and134134Algorithms on A1c and Frequency of Hypoglycemia9-31359.2.8 Severe Hypoglycemia9-3	115		
1179. Chapter 9: Statistical Considerations9-11189.1 Sample Size9-11209.2 Analysis Plan9-11219.2.1 Assessment of the Feasibility of Using the Navigator on a daily basis9-11229.2.2 Development and testing of Algorithms9-11239.2.3 Questionnaires9-11249.2.4 Inpatient Accuracy of the Navigator9-11259.2.4.1 Difference Measures9-11269.2.4.2 Precision9-21279.2.4.3 Detection of Hypoglycemia9-21289.2.4.4 Detection of Hyperglycemia9-21299.2.4.5 Assessment of Navigator Function during Exercise9-21309.2.4.6 Assessment of Navigator Function Post-Breakfast9-21319.2.5 Outpatient Accuracy of the Navigator9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and4.1gorithms on A1c and Frequency of Hypoglycemia9-31359.2.8 Severe Hypoglycemia9-3			
1199.1 Sample Size9-11209.2 Analysis Plan9-11219.2.1 Assessment of the Feasibility of Using the Navigator on a daily basis9-11229.2.2 Development and testing of Algorithms9-11239.2.3 Questionnaires9-11249.2.4 Inpatient Accuracy of the Navigator9-11259.2.4.1 Difference Measures9-11269.2.4.2 Precision9-21279.2.4.3 Detection of Hypoglycemia9-21289.2.4.4 Detection of Hyperglycemia9-21299.2.4.5 Assessment of Navigator Function during Exercise9-21309.2.4.6 Assessment of Navigator Function Post-Breakfast9-21319.2.5 Outpatient Accuracy of the Navigator9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and3134Algorithms on A1c and Frequency of Hypoglycemia9-31359.2.8 Severe Hypoglycemia9-3	117		
1199.1 Sample Size9-11209.2 Analysis Plan9-11219.2.1 Assessment of the Feasibility of Using the Navigator on a daily basis9-11229.2.2 Development and testing of Algorithms9-11239.2.3 Questionnaires9-11249.2.4 Inpatient Accuracy of the Navigator9-11259.2.4.1 Difference Measures9-11269.2.4.2 Precision9-21279.2.4.3 Detection of Hypoglycemia9-21289.2.4.4 Detection of Hyperglycemia9-21299.2.4.5 Assessment of Navigator Function during Exercise9-21309.2.4.6 Assessment of Navigator Function Post-Breakfast9-21319.2.5 Outpatient Accuracy of the Navigator9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and3134Algorithms on A1c and Frequency of Hypoglycemia9-31359.2.8 Severe Hypoglycemia9-3		9. Chapter 9: Statistical Considerations	
1209.2 Analysis Plan9-11219.2.1 Assessment of the Feasibility of Using the Navigator on a daily basis9-11229.2.2 Development and testing of Algorithms9-11239.2.3 Questionnaires9-11249.2.4 Inpatient Accuracy of the Navigator9-11259.2.4.1 Difference Measures9-11269.2.4.2 Precision9-21279.2.4.3 Detection of Hypoglycemia9-21289.2.4.4 Detection of Hyperglycemia9-21299.2.4.5 Assessment of Navigator Function during Exercise9-21309.2.4.6 Assessment of Navigator Function Post-Breakfast9-21319.2.5 Outpatient Accuracy of the Navigator9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and134134Algorithms on A1c and Frequency of Hypoglycemia9-31359.2.8 Severe Hypoglycemia9-3			
1219.2.1 Assessment of the Feasibility of Using the Navigator on a daily basis9-11229.2.2 Development and testing of Algorithms9-11239.2.3 Questionnaires9-11249.2.4 Inpatient Accuracy of the Navigator9-11259.2.4.1 Difference Measures9-11269.2.4.2 Precision9-21279.2.4.3 Detection of Hypoglycemia9-21289.2.4.4 Detection of Hyperglycemia9-21299.2.4.5 Assessment of Navigator Function during Exercise9-21309.2.4.6 Assessment of Navigator Function Post-Breakfast9-21319.2.5 Outpatient Accuracy of the Navigator9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and9-3134Algorithms on A1c and Frequency of Hypoglycemia9-31359.2.8 Severe Hypoglycemia9-3			
1229.2.2 Development and testing of Algorithms9-11239.2.3 Questionnaires9-11249.2.4 Inpatient Accuracy of the Navigator9-11259.2.4.1 Difference Measures9-11269.2.4.2 Precision9-21279.2.4.3 Detection of Hypoglycemia9-21289.2.4.4 Detection of Hyperglycemia9-21299.2.4.5 Assessment of Navigator Function during Exercise9-21309.2.4.6 Assessment of Navigator Function Post-Breakfast9-21319.2.5 Outpatient Accuracy of the Navigator9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and9-3134Algorithms on A1c and Frequency of Hypoglycemia9-31359.2.8 Severe Hypoglycemia9-3			
1239.2.3 Questionnaires.9-11249.2.4 Inpatient Accuracy of the Navigator.9-11259.2.4.1 Difference Measures9-11269.2.4.2 Precision.9-21279.2.4.3 Detection of Hypoglycemia9-21289.2.4.4 Detection of Hyperglycemia9-21299.2.4.5 Assessment of Navigator Function during Exercise9-21309.2.4.6 Assessment of Navigator Function Post-Breakfast.9-21319.2.5 Outpatient Accuracy of the Navigator9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and9-3134Algorithms on A1c and Frequency of Hypoglycemia9-31359.2.8 Severe Hypoglycemia9-3			
1249.2.4 Inpatient Accuracy of the Navigator9-11259.2.4.1 Difference Measures9-11269.2.4.2 Precision9-21279.2.4.3 Detection of Hypoglycemia9-21289.2.4.4 Detection of Hyperglycemia9-21299.2.4.5 Assessment of Navigator Function during Exercise9-21309.2.4.6 Assessment of Navigator Function Post-Breakfast9-21319.2.5 Outpatient Accuracy of the Navigator9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and9-3134Algorithms on A1c and Frequency of Hypoglycemia9-31359.2.8 Severe Hypoglycemia9-3		1 0 0	
1259.2.4.1 Difference Measures9-11269.2.4.2 Precision9-21279.2.4.3 Detection of Hypoglycemia9-21289.2.4.4 Detection of Hyperglycemia9-21299.2.4.5 Assessment of Navigator Function during Exercise9-21309.2.4.6 Assessment of Navigator Function Post-Breakfast9-21319.2.5 Outpatient Accuracy of the Navigator9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and9-3134Algorithms on A1c and Frequency of Hypoglycemia9-31359.2.8 Severe Hypoglycemia9-3			
1269.2.4.2 Precision.9-21279.2.4.3 Detection of Hypoglycemia9-21289.2.4.4 Detection of Hyperglycemia9-21299.2.4.5 Assessment of Navigator Function during Exercise9-21309.2.4.6 Assessment of Navigator Function Post-Breakfast9-21319.2.5 Outpatient Accuracy of the Navigator9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and9-3134Algorithms on A1c and Frequency of Hypoglycemia9-31359.2.8 Severe Hypoglycemia9-3			
1279.2.4.3 Detection of Hypoglycemia			
1289.2.4.4 Detection of Hyperglycemia9-21299.2.4.5 Assessment of Navigator Function during Exercise9-21309.2.4.6 Assessment of Navigator Function Post-Breakfast9-21319.2.5 Outpatient Accuracy of the Navigator9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and9-3134Algorithms on A1c and Frequency of Hypoglycemia9-31359.2.8 Severe Hypoglycemia9-3			
1299.2.4.5 Assessment of Navigator Function during Exercise9-21309.2.4.6 Assessment of Navigator Function Post-Breakfast9-21319.2.5 Outpatient Accuracy of the Navigator9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and9-3134Algorithms on A1c and Frequency of Hypoglycemia9-31359.2.8 Severe Hypoglycemia9-3			
1309.2.4.6 Assessment of Navigator Function Post-Breakfast			
1319.2.5 Outpatient Accuracy of the Navigator9-21329.2.6 Comparison of Subject vs. Staff Freestyle Measurements9-21339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and9-3134Algorithms on A1c and Frequency of Hypoglycemia9-31359.2.8 Severe Hypoglycemia9-3			
1329.2.6 Comparison of Subject vs. Staff Freestyle Measurements		•	
1339.2.7 Exploratory Assessment of the Effect of Use of the Navigator and Algorithms on A1c and Frequency of Hypoglycemia			
134Algorithms on A1c and Frequency of Hypoglycemia9-31359.2.8 Severe Hypoglycemia9-3			
135 9.2.8 Severe Hypoglycemia			0_3
51 05			
		7.2.0 bevere rrypogrycennu	

137	10. References	10-1
-----	----------------	------

1.00	
138	CHAPTER 1
139	INTRODUCTION
140	11 Inter des d'an and Dathenals
141 142	1.1 Introduction and Rationale
142 143	Resistance to frequent blood glucose monitoring is a major impediment to attaining good (lower HbA1a love)) glucose control. The Diabetes Control and Complications Trial (DCCT)
145 144	HbA1c level) glucose control. The Diabetes Control and Complications Trial (DCCT) convincingly proved that glucose control closer-to-normal range ("tight" glycemic control) reduced
144 145	
145 146	the likelihood of the eye, kidney, and nerve complications of diabetes. Increasing the frequency of glucose monitoring was an important aspect of attaining improved glucose control in the DCCT.
140	As a result of the DCCT, many physicians have attempted to keep children and adults in very
147	"tight" glucose control. Unfortunately, the DCCT study also showed that the incidence of severe
148	hypoglycemia was three times higher in the intensively treated group compared with the standard
149	treatment group. The tools to safely implement tight glycemic control were not available to the
150	DCCT. The Navigator TM by TheraSense has been developed to assist in closer monitoring of
151	glucose levels.
152	
155	The proper role of the Navigator in the management of type 1 diabetes in children has not been
155	determined. We are planning a randomized clinical trial (RCT) to compare the effect on glycemic
156	control, hypoglycemia, and quality of life of using a Navigator versus standard care. As a prelude
157	to the RCT, we will conduct a pilot study in which subjects will use the Navigator in their home
158	environment. The objectives of the pilot study will include:
159	• Assessment of the feasibility of using the Navigator continuous glucose sensor on a daily
160	basis
161	• Development and testing of algorithms for making adjustments to diabetes management
162	based on data from Navigator
163	• Assessment of accuracy of the Navigator
164	• Assessment of Navigator function during exercise and during a period of meal-induced
165	hyperglycemia
166	• Exploratory assessment of the effect of use of the Navigator and algorithms on A1c and
167	frequency of hypoglycemia
168	
169	
170	1.2 Background on the Navigator
171	The Navigator was developed by TheraSense, Inc. This sensor uses a glucose oxidase based
172	electrochemical sensor, and is designed to measure blood glucose levels in a range of 20-500 mg/dl.
173	The sensor is inserted subcutaneously and measures interstitial glucose. In human studies the
174	interstitial glucose levels generally lag behind the blood glucose by 3 to13 minutes. ^{1,2}
175	
176	The Navigator, provides a glucose reading every 60 seconds (or 1440 readings a day). Each sensor
177	is designed to provide readings for up to 120 hours. It has alarms for hypoglycemia and
178	hyperglycemia and for projected high and low glucose values. The alarm set points can be adjusted
179	by the user. The Navigator also has a trend arrow indicating the glucose rate of change (>-2
180	mg/dL/min, -2 to -1 mg/dL/min, -1 to 1 mg/dL/min, 1 to 2 mg/dl/min, and >2 mg/dl/min). Subjects
181	can enter events, such as when they took insulin, ate, or exercised. The sensor requires calibration
182	values to be entered 3 times during the first day of wear at 1hour, 3 hours, and 24 hours and does
183	not require additional calibration values. The values are entered directly into the Navigator which
184	has a TheraSense Freestyle home glucose meter built into the unit. The Navigator has not yet been
185 186	approved by the FDA. The Navigator currently under review by the FDA will limit sensor wear to 3 days
100	N HANN

186 3 days.

- 187 **1.3 Synopsis of Study Protocol**
- 188 189 Study Design/Sample Size: Pilot study with approximately 30 subjects. 190 191 **Summary of Protocol** 192 1. Informed consent is obtained from eligible subjects (age 3 to <18 years, T1D for >1 year, 193 downloadable insulin pump being used, computer with internet access available at home). 194 2. On the day of enrollment, a hemoglobin A1c is obtained, psychosocial questionnaires are 195 completed, and instructions are given for use of the Navigator sensor. The study personnel will 196 supervise the subject or parent inserting the Navigator sensor in the clinic and will instruct the 197 subject or parent to insert a second sensor at home in 5 days (or sooner if the sensor stops 198 working or is pulled out). To obtain a baseline assessment of glycemic variability, the 199 Navigator used during the first week will be blinded so subjects will not be able to view the data 200 from the sensor. The subject will be instructed to complete at least four glucose measurements a 201 day using the Freestyle meter built into the device. 202 3. The subject will return for a 24-hour CRC admission approximately one week (7-12 days) after 203 the enrollment visit. An approximately equal number of subjects will insert a new sensor 4, 3, 2, and 1 day prior to the admission to allow for assessment of accuracy over the lifespan of the 204 205 sensor. 206 Areas where a Navigator sensor was worn during the first week will be assessed by study • 207 personnel for any skin irritation. 208 Subjects will continue using the blinded Navigator sensor last inserted at home and a second 209 new sensor will be inserted by the subject or parent with supervision by study personnel. 210 An intravenous catheter will be inserted for reference glucose measurements, which will be • 211 drawn every 30 minutes during the admission to send to a central laboratory to assess 212 accuracy of the Navigator. 213 The accuracy of subject/parent blood glucose testing using the Freestyle HGM will be 214 compared with the testing performed by trained study personnel using the same meter. 215 The accuracy of the subject's HGM being used at home may be tested. • 216 The accuracy of other commercially-available home glucose meters may also be examined. • There will be no additional blood requirements to perform this testing. 217 218 • For subjects >7 years old, an exercise session of moderate intensity will be completed in the 219 afternoon. This will allow for assessment of function of the Navigator during exercise and 220 assessment of the accuracy of detecting changes in blood glucose. 221 For subjects of sufficient weight to accommodate the volume of blood required, blood 222 glucose measurements will be made every 10 minutes for one hour after breakfast. This will 223 allow for assessment of the accuracy of the Navigator in detecting change during a period of rising blood glucose. 224 225 The pre-admission Navigator, HGM, and pump data will be reviewed and changes will be • 226 made to diabetes management as needed. Subjects and parents will be provided with 227 extensive teaching to use the protocol-developed algorithms for changes to diabetes 228 management to be used in real time based on Navigator data after the subject leaves the 229
- 230 4. Each subject will be provided with the instructions for downloading the Navigator.

CRC.

- 5. A follow-up visit will be performed at 1, 3, 7, and 13 weeks after the CRC admission. The visit windows will be <u>+</u>3 days at weeks 1, 3, and 7 and <u>+</u>1 week for week 13. Subjects may be asked to insert a new sensor 5 days before some of the visits to allow for skin assessments by study personnel after the sensor has been worn for 5 days.
- At each visit, the Navigator will be downloaded, diabetes management will be reviewed, and compliance with use of the algorithms will be assessed. A study investigator will review the glucose data generated by the Navigator, trends and, in conjunction with the nurse coordinator make treatment recommendations. This will continue until enough collective experience has developed for the nurse coordinator to make the insulin adjustments more autonomously.
- At each visit, the subject's BG will be tested on his/her Freestyle meter and a Freestyle meter at the clinic to assess the accuracy of the home meters over time.
- At the 3, 7, and 13-week visits, a psychosocial questionnaire regarding the frequency and convenience of use of the algorithms will be administered.
- At the 7-week visit, HbA1c will be measured
- At the 13-week visit, HbA1c will be measured and psychosocial questionnaires will be administered.
- 6. Phone contacts will be made with the subjects after 3 days (±1 day), then at 2, 4, 8, and 10
 weeks (±3 days) following the CRC admission to review their diabetes management and assess
 compliance with use of the algorithms. Phone contacts will also involve collection of diet data
 as well as any illnesses, stressful events, and menstrual cycle data for females.
- At the 13-week visit, subjects who are interested in continuing to use the Navigator will
 continue in the study for another 13 weeks. Subjects who are not interested will be discontinued
 from the study.
- 8. Subjects continuing in the study will be provided with additional sensors and instructed to use
 them as frequently as they would like. Subjects will also be instructed to continue using the
 algorithms for diabetes management.
- At the 26-week visit, psychosocial questionnaires regarding the satisfaction with the
 Navigator as well as the algorithms will be administered, frequency of use of the sensors and
 continued compliance with use of algorithms will be assessed, and HbA1c will be measured.
- 261

262 263	CHAPTER 2 SUBJECT ELIGIBILITY AND ENROLLMENT
264 265 266 267	2.1 Study Population Approximately 30 subjects will be enrolled in this study at five clinical centers with approximately 6 enrolled at each center.
268 269 270 271	Enrollment will include approximately 10 subjects in each of the age groups of 3.0 to <7.0 years old, 7.0 to <12.0 years old, and 12.0 to <18.0 years old.
272 273 274	Subjects will include both males and females and an enrollment goal will be to achieve an approximately equal sex distribution in each age group.
275 276	A goal of recruitment will be to enroll approximately 10% minorities.
277 278 279	 2.2 Eligibility and Exclusion Criteria 2.2.1 Eligibility To be eligible for the study, all subjects must meet the following criteria:
279 280 281 282	 Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one year The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed.
283	2) Age 3.0 years to less than 18.0 years
284	3) Subject has used a downloadable insulin pump for at least 6 months
285	4) Parent/guardian and subject understand the study protocol and agree to comply with it
286 287 288 289	5) Subjects ≥9.0 years old and primary care giver (i.e., parent or guardian) comprehend written English This requirement is due to the fact that the questionnaires to be used as outcome measures do not have validated versions in Spanish or other languages.
290	6) Subject has a home computer with internet access
291	7) For females, subject not intending to become pregnant during the next 3 months
292 293	 8) No expectation that subject will be moving out of the area of the clinical center during the next 3 months
294 295 296	 Informed Consent Form signed by the parent/guardian and Child Assent Form signed by the subject
297 298 299 300	 2.2.2 Exclusion Subjects who meet any of the following criteria are <u>not</u> eligible for the study: 1) The presence of a significant medical disorder that in the judgment of the investigator will affect the wearing of the sensors or the completion of any aspect of the protocol.
301 302 303	 2) The presence of any of the following diseases: Asthma if treated with systemic or inhaled corticosteroids in the last 6 months Cystic fibrosis
304 305	• Other major illness that in the judgment of the investigator might interfere with the completion of the protocol

- 306 Adequately treated thyroid disease and celiac disease do not exclude subjects from
 307 enrollment
- 309 3) Inpatient psychiatric treatment in the past 6 months for either the subject or the subject's
 310 primary care giver (i.e., parent or guardian).
- 311

- 4) Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the
 investigator would be a contraindication to participation in the study.
- 314

315 **2.3 Patient Enrollment and Baseline Data Collection**

316 Potential subjects will be evaluated for study eligibility through the elicitation of a medical history 317 and performance of a physical examination by a study investigator.

318

319 2.3.1 Historical Information and Physical Exam

A history will be elicited from the subject and parent and extracted from available medical records with regard to the subject's diabetes history and current diabetes management. A standard physical exam (including vital signs and height and weight measurements) will be performed by the study investigator or his or her designee (a pediatric endocrinologist, pediatric endocrine fellow, or a pediatric endocrine nurse practitioner).

325

326 **2.3.2 Informed Consent**

For eligible subjects, the study will be discussed with the subject and parent/legal guardian (referred to subsequently as 'parent'). The parent will be provided with the Informed Consent Form to read

- 329 and will be given the opportunity to ask questions. Subjects will either be given the Child Assent
- Form to read or it will be read to the child. If the parent and child agree to participate, the Informed
- 331 Consent Form and Child Assent Form will be signed. A copy of the consent form will be provided 332 to the subject and his/her parent and enother copy will be added to the subject's aligie short
- to the subject and his/her parent and another copy will be added to the subject's clinic chart.
- 333

334 Written informed consent must be obtained from the parent or guardian prior to performing any

- 335 study-specific procedures that are not part of the subject's routine care.
- 336

337 2.3.2.1 Authorization Procedures

338 As part of the informed consent process, each subject will be asked to sign an authorization for

release of personal information. The investigator, or his or her designee, will review what study

340 specific information will be collected and to whom that information will be disclosed. After

341 speaking with the subject and their parent, questions will be answered about the details regarding 342 authorization.

342 343

344 2.3.2.2 Special Consent Issues

The study population for this study includes children and adolescents. The consent form and study procedures will be discussed with each subject at a level in which they can understand. The study

347 staff will ask questions of each subject to assess the autonomy and understanding of the study.

Each subject will be asked to sign an assent form, if appropriate for the subject's age. Additionally,

- 349 the parent(s) and/or guardian(s) of each subject will be asked to sign the consent form. They will be
- 350 given the opportunity to ask questions throughout the study on all study related procedures.
- 351

352 2.3.3 Hemoglobin A1c Determination

The DCA 2000 will be used for baseline measurement of hemoglobin A1c and diabetes

- 354 management decisions.
- 355

356 2.3.4 Questionnaire Completion

- 357 The following questionnaires will be completed. They are described in chapter 6.
 - PedsQL Diabetes Module
 - Diabetes Self Management Profile (Treatment Adherence Questionnaire)

360361 2.3.5 Instructions for Home Procedures

Each subject will be provided with a Navigator and sensors. The Navigator will be blinded and
 subjects will not be able to view the Navigator data during the first week of the study. The subject

and parent/guardian will be instructed to use the Navigator on a daily basis and will be instructed in

the use of the device including calibration of the device using the built-in Freestyle meter. In order to assess accuracy throughout the lifespan of the sensor, approximately 25% of the subjects will be

367 asked to insert a new Navigator sensor four days before the scheduled CRC admission,

368 approximately 25% three days before the admission, approximately 25% two days before the

admission, and approximately 25% one day before the scheduled CRC admission.

370

358

359

371 The subjects will be able to view the results of the Freestyle testing and will be instructed to

- 372 perform at least 4 blood glucose measurements per day prior to the CRC admission. The
- 373 measurements will be performed prior to each meal and before bed.

374	CHAPTER 3				
375 376	INPATIENT CRC ADMISSION				
377					
378 379	About one week following the enrollment visit, subjects will have an inpatient CRC admission of approximately 24 hours.				
380 381	• Areas where a Navigator sensor was worn during the first week will be assessed by study personnel for any skin irritation.				
382 383	• Subjects will continue using the blinded Navigator sensor last inserted at home and a second new sensor will be inserted by the subject or parent with supervision by study personnel.				
384 385 386	• An intravenous catheter will be inserted for reference glucose measurements, which will be drawn every 30 minutes during the admission to send to a central laboratory to assess accuracy of the Navigator.				
387 388	• The accuracy of subject/parent blood glucose testing using the Freestyle HGM will be compared with testing performed using the same meter by study personnel.				
389	• The accuracy of the subject's HGM used at home may be tested.				
390	• The accuracy of other commercially-available home glucose meters may also be examined.				
391 392	• For subjects ≥7 years old, an exercise session of moderate intensity will be completed in the afternoon.				
393 394	• For subjects of sufficient weight to accommodate the volume of blood required, blood glucose measurements will be made every 10 minutes for one hour after breakfast.				
395 396 397 398 399	• The preadmission Navigator, HGM, and pump data will be reviewed and changes will be made to diabetes management as needed. Subjects and parents will be provided with extensive teaching to use the protocol-developed algorithms for changes to diabetes management to be used in real time based on Navigator data after the subject leaves the CRC.				
400					
401	3.2 Navigator Management and Procedures				
402	3.2.1 Navigator Placement				
403 404	,				
405					
406	Subjects will continue to wear the sensor that was placed at home. If it is not functioning at the				
407	time of admission, a new sensor will be inserted.				
408					
409	A second Navigator sensor will be placed by the subject or parent while being supervised by				
410					
411					
412 413	Calibration of the Newigator will be performed by study/CPC personnel. Freestyle readings for				
415	Calibration of the Navigator will be performed by study/CRC personnel. Freestyle readings for calibration will be made to coincide with reference measurements.				
415	canoration will be made to contende with reference incastrements.				
416	3.2.2 Sensor Failure				
417	If a Navigator sensor fails with fewer than 4 hours of reference measurements remaining, it will not				

418 be replaced.

420 **3.3 Reference Glucose Measurements**

- 421 An intravenous catheter will be inserted in an arm vein. The area where the catheter will be inserted 422 may be numbed with Elamax or EMLA cream prior to catheter insertion.
- 423
- 424 The reference measurements will be timed to be on the half-hour. If the catheter stops functioning,425 it may be replaced at the discretion of the investigator.
- 426
- 427 The clinical centers either will use reinfusion of blood or will discard blood with each blood draw,
- 428 depending on the standard practice at each center's CRC. The blood draws will be performed by
- 429 the method in standard use at the CRC. The blood samples will be sent to a central lab.
- 430

431 **3.3.1 Volume of Blood Draws**

- 432 Each blood draw will require a blood volume of approximately 1.3 ml per blood draw at the
- 433 "discard" centers and 0.3 ml per blood draw at the "reinfusion" centers. At the "discard" centers,
- the maximum number of blood draws based on the subject's weight will be calculated at the time of
- 435 admission so that the maximum blood volume drawn will not exceed 5% (at reinfusion centers, the
- 436 maximum blood volume drawn will not approach 5%). Section 7.5.7 provides further details on the
- 437 blood volume requirements.

438

439 3.3.2 Quality Control Specimens

- 440 Approximately 5% of the reference blood samples will be collected in duplicate to send to the 441 central lab for quality control purposes.
- 442

443 **3.4 Glucose Measurements with the Study Home Glucose Meter**

- 444 Bedside blood glucose monitoring will be performed using the Freestyle meter built into the
- 445 Navigator. If the need for a Freestyle blood glucose measurement does not coincide with a
- reference blood draw, a fingerstick may be done to obtain capillary blood for the glucose
- 447 measurement. If a fingerstick test is performed, the subject or parent will perform a BG test at the
- same time study personnel perform the BG test on the Freestyle meter in order to assess the
- 449 accuracy of subject/parent testing compared with the study personnel. Calibrations for the450 Navigator will be performed by the CRC staff using fingerstick tests.
- 451

452 **3.5 Blood Glucose Testing for Hypoglycemia**

- 453 If either a subject reports symptoms of hypoglycemia or a Navigator hypoglycemia alarm occurs
- 454 (for low blood glucose), the blood glucose will be checked on the Freestyle meter.
- 455
- 456 A reference blood draw will be done if the Freestyle value is \leq 70 mg/dL. A reference draw will be
- 457 made every 10 minutes until the BG is >70 mg/dL on the Freestyle meter. For subjects <7, a
- 458 reference blood draw will be done if the Freestyle value is $\leq 80 \text{ mg/dL}$ and additional draws will be 459 made every 10 minutes until the BG is > 80 mg/dL.
- 459 460
- 461 If an extra reference blood draw falls within 10 minutes of the next scheduled blood draw, then the462 next scheduled blood draw will be skipped.
- 463


464 **3.6 Exercise Session**

- For subjects \geq 7 years of age, the exercise session will be performed in the afternoon. The basal rate
- normally used at home on a sedentary day will be used by subjects during the CRC admission. In
 order to enhance the assessment of the Navigator's ability to detect hypoglycemia, the basal rate
- 468 will be continued during the exercise session.

- 469
- 470 Approximately 2 hours and again 1 hour before the scheduled start time for the exercise session, the
- BG will be checked with the Freestyle meter. Insulin or a snack may be given at the discretion of 471
- 472 the investigator at either time to try to have the starting BG level between 80 and 200 mg/dL.
- 473
- 474 Exercise will not begin if the subject's blood glucose is <80 mg/dL as measured by the Freestyle 475 meter. If the blood glucose level is 80 - 120 mg/dL, the subject will be given a snack of 15-30g of 476 carbohydrates and the exercise will begin.
- 477

478 Exercise will consist of 15 minutes on a treadmill at a heart rate of approximately 140 followed by a 479 5-minute rest period. This cycle will be repeated 3 more times for a total of four 15-minute exercise 480 periods with 5-minute rest periods in between (75 minutes total). Subjects will be encouraged to 481 complete the exercise but will not be coerced to complete any remaining cycles if they are unable. 482 If the 4 cycles are not completed in 2 hours, the exercise will be stopped. A heart rate monitor will 483 be worn throughout the time of exercise to ascertain the effort exerted.





♠ ♠ HGM blood glucose and venous samples collected for reference blood glucose

494 495

491

492 493

496 If during exercise the BG drops to <70 mg/dL the subject will be given 15-30g of carbohydrate and 497 after 5-15 minutes, the BG will be rechecked. Exercise will not resume until the BG is >80 mg/dL. 498

499 **3.7 Post-breakfast Glucose Measurements**

500 In subjects of appropriate weight to accommodate the volume of blood required for testing, the

501 Navigator will be assessed following a physiologic rise in blood glucose after breakfast.

502

503 Before starting the post-breakfast glucose measurements, a Freestyle blood glucose level will be 504 obtained. If the blood glucose level is >250 mg/dl, then the subject's usual insulin correction dose 505 will be given with breakfast. The meal dose (the dose for the carbohydrates to be consumed) will 506 not be given with breakfast, but will be given after the completion of the 10-minute blood draws. 507 The breakfast insulin correction dose (and the meal dose to cover the carbohydrate consumed) will 508 be withheld until after completion of the reference glucose sampling if the blood glucose level is 509 <250 mg/dL.

510

511 Reference glucose levels will be obtained at baseline (when the subject finishes breakfast) and every 10 minutes for 60 minutes. 512

513

514 **3.8 Diabetes Management**

515 Insulin management will follow the same routine that the subject was following at home prior to the

516 hospitalization. Insulin doses will be determined by parents or subjects in consultation with the

517 study investigator or his/her designee. For management, blood glucose levels from the Freestyle

meter will be used. 518

- 519
- 520 Standard hypoglycemia treatment will be given for glucose values \leq 70 mg/dl in children 7 years of
- 521 age or older and for glucose values ≤ 80 mg/dl in children less than 7 years old (approximately 10
- 522 grams of carbohydrate--e.g., glucotablets or juice--for children less than age 7 and approximately 15 523 grams of carbohydrate for children 7 or older; with a recheck of the blood glucose 10 minutes later).
- 523 524

525 For two consecutive glucose values >300 mg/dl, a urine or serum ketone level will be determined.

527 **3.9 Algorithms for Diabetes Management**

- 528 During the CRC admission, the Navigator, insulin pump, and HGM data from the pre-admission
- 529 week will be reviewed with the subject and parent. The subjects and parents will be taught how to
- 530 make changes to the diabetes management based on the data from the Navigator.
- 531

532 **3.10 Daily Activities**

- 533 Subjects will be permitted to perform their usual indoor activities during the hospitalization.
- 534

535 **3.11 Diet**

- 536 The prescribed diet will be at the discretion of the investigator.
- 537

538 **3.12 Hospital Discharge**

- 539 Prior to discharge, the blinded Navigator sensor will be removed and a CRC nurse and a study nurse
 540 or investigator will independently assess the skin in the area of each Navigator sensor insertion (see
 541 section 3.2.1).
- 542
- 543 Subjects will continue wearing the unblinded Navigator inserted at the time of admission and will
- be provided with additional sensors. The subject and parent/guardian will be instructed to use the
- 545 Navigator on a daily basis and will be instructed in the use of the device including calibration of the
- 546 device using the built-in Freestyle meter and downloading the device.
- 547

548

549	CHAPTER 4
550	HOME PROCEDURES AND DIABETES MANAGEMENT
551	
552	4.1 Home Glucose Monitor
553	Subjects will use the Freestyle as required for calibration of the Navigator sensor. Additional blood
554	glucose measurements may be performed by the subject at anytime.
555	
556	4.2 Frequency of Use of the Navigator
557	Each subject will be asked to use a Navigator sensor on a daily basis, inserting a new sensor every 5
558	days or sooner if the sensor stops working or is pulled out.
559	
560	Subjects will be instructed to insert a new sensor 5 days before the 3-week and 13-week visits. This
561	will allow for skin assessments to be made following the removal of sensors after 5 days of use.
562	
563	4.3 Instructions for Use of the Navigator
564	The subject and parent will be instructed on use of the Navigator and will be provided with a
565	manual describing its calibration and use.
566	
567	4.4 Downloading the Navigator
568	At specified intervals, each subject will download the Navigator data, which will be transmitted to
569	the Coordinating Center. The steps to follow will be detailed in the subject instruction manual.
570	
571 572	4.5 Self-assessment Using Navigator Download
572	Instructions will be provided for subjects and parents to download and review the Navigator glucose
573	values.
574 575	The cools for blood always levels will be as follows:
575	The goals for blood glucose levels will be as follows:
576	• Fasting: 70-150 mg/dl
577	• Premeal: 70-150 mg/dl
578	• Two hours after each meal: 70-180 mg/dl
579	• Bedtime: 90-150 mg/dl
580	• 12a.m. to 4a.m. : 80-150 mg/dl
581	
582	The aim is to have at least half of the values for each time of day within these ranges.
583	
584	4.6 Algorithms for Diabetes Management Decisions
585	The clinical center will provide the subject or primary care giver with algorithms to make
586	management decisions based on real-time data provided by the Navigator and Freestyle meter. The
587	algorithms will be reviewed with the subject and parent during the CRC admission, at each follow-
588	up visit, and during each phone contact.
589	Compliance with using electrithms will be accessed during phone calls and follow up visite
590	Compliance with using algorithms will be assessed during phone calls and follow-up visits.
591 502	
592 593	
593 594	
271	
595 596 597	

598 599	CHAPTER 5 FOLLOW-UP
600	
601	5.1 Timing of Visits
602	Follow-up visits will be completed at 1, 3, 7, and 13 weeks following the CRC admission. The visit
603	windows will be ± 3 days at weeks 1, 3, and 7 and ± 1 week for week 13.
604	
605	5.2 Overview
606	The main purpose of the follow-up visits is to review the data from the Navigator, pump, and
607	Freestyle meter, review compliance with use of the algorithms, and make any necessary adjustments
608	for diabetes management. The investigators will review the data and will, in conjunction with the
609	nurse coordinators, implement all insulin adjustments.
610	At each visit a skin assessment will be nonformed where the Newigston has been used. The
611	At each visit, a skin assessment will be performed where the Navigator has been used. The
612 613	accuracy of the subject's Freestyle meter will be assessed by comparing a blood glucose result
613 614	obtained on the subject's meter to a simultaneous test performed on a Freestyle meter in the clinic.
614 615	At the 3, 7, and 13-week visits, the Insulin Dose Adjustment Guidelines Satisfaction Questionnaire
616	will be administered (this questionnaire is described in Chapter 6).
617	win be administered (this questionnane is described in Chapter 0).
618	At the 7-week follow-up visit, the following also will be done in addition to a standard clinic visit:
619	 HbA1c determination using the DCA 2000
620	• HOATE determination using the DEA 2000
620 621	At the 13-week follow-up visit, the following also will be done in addition to a standard clinic visit:
622	 HbA1c determination using the DCA 2000
623	 Completion of questionnaires (the questionnaires are described in Chapter 6)
623 624	 PedsQL Diabetes Module
625	 Diabetes Self-Management Profile (Treatment Adherence Questionnaire)
626	 Continuous Glucose Monitor Satisfaction Scale
627	 Insulin Dose Adjustment Guidelines Satisfaction Questionnaire
628	
629	5.3 Continued use of the Navigator
630	At the 13-week visit, subjects not continuing the Navigator will be discontinued from the study.
631	
632	Subjects willing to continue using the Navigator will be given additional sensors and instructed to
633	use the sensors as often as they would like. These subjects will have a visit at 26 weeks. At the 26-
634	week visit, a skin assessment will be performed where the Navigator has been used and frequency
635	of continued use of the Navigator and algorithms will be assessed. The following will also be done
636	in addition to a standard clinic visit:
637	• Measurement of HbA1c
638	Completion of CGM Satisfaction Scale and Insulin Dose Adjustment Guidelines
639	Satisfaction Questionnaire
640	
641	5.4 Phone Calls to Subjects
642	Phone calls will be made from the clinical center to each subject or primary care giver 3 days (± 1
643	day) and 2, 4, 8 and 10 weeks (\pm 3 days) following the CRC admission. The primary purpose of the
644	calls will be to review the subject's diabetes management and make alterations as indicated. During

calls will be to review the subject's diabetes management and make alterations as indicated. During

645 each phone call, the coordinator will review the subject's diabetes management after discussion

646 with a study investigator. The downloaded Navigator data and Freestyle data will be available to

- 647 the clinical center for review during the call. Subjects will provide diet data as well as information
- 648 regarding any illnesses or stressful events. Female subjects will also be asked to provide menstrual
- 649 cycle information. The Procedure Manual will contain an outline for the clinical center to follow
- 650 during the call.

651 652	CHAPTER 6 QUESTIONNAIRES
653	
654	6.1 PedsQL Diabetes Module
655	This is a 28-item scale developed and validated for the measurement of diabetes-specific quality of
656	life. Separate forms have been validated for child self-report (2-4 year old; 5-7 year old; 8-12 year
657	old; and 12-18 year old) and parent report for these same age groups. Participants record the extent
658	to which they (or their child) experienced each of 28 problems related to diabetes in the prior
659	month. This questionnaire will be completed at enrollment and at the 13-week follow-up visit.
660	Administration time is approximately 15 minutes.
661	
662	6.2 Diabetes Self Management Profile (Treatment Adherence Questionnaire)
663	This is administered as a structured interview (DSMP) and will be used to determine if changes in
664	diabetes treatment adherence occur during use of the Navigator and to assess whether benefit from
665	use of the Navigator varies with the patient's level of treatment adherence. Parents and younger
666	children will be interviewed together, while parents and children ≥ 9 years old will be interviewed
667	separately. Since administration of the DSMP interview yields the most reliable and valid data if
668	administered by a person not otherwise associated with the diabetes team, all DSMP interviews will
669 670	be completed via phone by experienced staff at the Nemours Children's Clinic in Jacksonville, FL. The staff completing the interviews will be masked to the assignment group for the subjects. This
671	questionnaire will be completed at enrollment and at the 13-week follow-up visit. Administration
672	time is approximately 20 minutes.
673	time is approximately 20 minutes.
674	6.3 Continuous Glucose Monitor Satisfaction Scale
675	This 34-item questionnaire was designed for this study to measure the impact of using the Navigator
676	on family diabetes management, general family relationships, and individual emotional, behavioral
677	and cognitive reactions to use of the device. This questionnaire will be completed at the 13-week
678	and 26-week follow-up visits. Administration time is approximately 15 minutes.
679	
680	6.4 Insulin Dose Adjustment Guidelines Satisfaction Questionnaire
681	This questionnaire was developed and will be piloted for this study to measure the frequency and
682	convenience of use of study-developed algorithms and satisfaction with use of the algorithms in
683	conjunction with the Navigator. This questionnaire will be completed at the 3-week, 7-week, 13-
684	week and 26-week follow-up visits. Data from the pilot study will be used to evaluate the measure's
685	psychometric properties including internal consistency, parent-adolescent agreement, associations
686	with study outcomes and descriptive statistics. Administration time is approximately 10 minutes.
687	
688	

689	CHAPTER 7
690 691	ADVERSE EVENTS
692	7.1 Events To Be Reported
693	Adverse event reporting will include (1) events that meet criteria for a serious adverse event (SAE),
694	(2) unanticipated adverse device events, (3) events that are considered to have a possible (or
695	greater) relationship to the Navigator or any study procedure, (4) hyperglycemia resulting in
696	diabetic ketoacidosis or hyperosmolar nonketotic coma, and (5) hypoglycemia resulting in seizures
697	or loss of consciousness.
698	After 7 days following the completion of concernse and all study means dynamic only advance asserts
699 700	After 7 days following the completion of sensor use and all study procedures, only adverse events with a possible or greater relationship to sensor use or study procedures will be reported.
700	with a possible of greater relationship to sensor use of study procedures with be reported.
701	7.2 Definitions
703	Adverse events meeting the above reporting criteria will be reported with reference to: time and
704	date of event, relationship to the device, severity, and final outcome.
705	
706	An adverse event is considered a Serious Adverse Event (SAE) when it meets one or more of the
707	following criteria: (1) death, (2) life-threatening, (3) required or prolonged hospitalization, (4)
708 700	permanent disability, or (5) required intervention to prevent permanent impairment/damage.
709 710	An Unanticipated Adverse Device Event is defined as an adverse event caused by, or associated
711	with, a device, if that effect or problem was not previously identified in nature, severity, or degree
712	of incidence.
713	
714	The relationship of any adverse event to the device or any other aspect of study participation will be
715	assessed and graded by a study investigator on a four-point scale: (1) not related, (2) possible, (3)
716	probable, and (4) definite. The intensity of adverse events will be rated on a three-point scale: (1)
717	mild, (2) moderate, or (3) severe. It is emphasized that the term severe is a measure of intensity:
718 719	thus a severe adverse event is not necessarily serious. For example, itching for several days may be rated as severe, but may not be clinically serious.
719	rated as severe, but may not be chinically serious.
721	7.3 Reporting Requirements for Serious and/or Unexpected Adverse Events
722	Any serious or unexpected adverse event occurring during or within 7 days after completion of the
723	study will be reported to the Coordinating Center within one working day of occurrence. A written
724	report on such an event will be sent to the Coordinating Center within five days of occurrence,
725	stating a description of the reaction, any required intervention, and the outcome. Each principal
726	investigator is responsible for informing his/her IRB of serious study-related adverse events and
727	abiding by any other reporting requirements specific to their IRB. Contact information for the
728	Coordinating Center is located in the front of the protocol as well as in the Study Directory.
729 730	7.4 Data and Safety Monitoring Board
730	An independent Data and Safety Monitoring Board will approve the protocol prior to its initiation
732	and will be informed of all serious adverse events and any unanticipated adverse device events that
733	occur during the study.
734	
735	7.5 Risks And Discomforts

736 **7.5.1 Navigator**

737 There is a low risk for developing a local skin infection at the site of the sensor needle placement.
738 Itchiness, redness, bleeding, and bruising at the insertion site may occur as well as local tape

- 739 allergies. The TheraSense application for FDA approval of the Navigator sensor proposes a 3-day
- 740 wearing period for each sensor. Nonetheless, TheraSense has indicated to DirecNet that a 5-day
- 741 wearing period should be safe, effective, and more acceptable to patients. With the 5-day wearing
- 742 period proposed for this study, the risk of skin reactions may increase. During the CRC admission
- 743 and at each follow-up visit, each site where the Navigator has been worn will be assessed by study
- 744 personnel. Both erythema and edema/induration will be scored on a 0 to 4 scale (as described on
- 745 the case report form and in the Procedures Manual). If the sum of the erythema score and the
- 746 edema/induration score is 6 or greater, an Adverse Event Form will be completed.
- 747

748 7.5.2 Fingerstick Blood Glucose Measurements

- 749 Fingersticks may produce pain and/or ecchymosis at the site.
- 750

751 7.5.3 Psychosocial Questionnaires

- 752 As part of the study, subjects and parents will complete psychosocial questionnaires which include
- 753 questions about their private attitudes, feelings and behavior related to diabetes. It is possible that
- 754 some people may find these questionnaires to be mildly upsetting. Similar questionnaires have been
- 755 used in previous research and these types of reactions have been uncommon.
- 756

757 7.5.4 IV Risks

- 758 A hollow needle/plastic tube will be placed in the arm for taking blood samples or giving fluids
- 759 during the CRC admission. This will be left in for 24 hours. When the needle goes into a vein, it can
- cause pain. A special cream (Elamax or EMLA®) may be used to numb the area where the needle 760 761
- will be inserted. The most common risks related to putting the numbing cream on the skin are
- 762 redness, blanching (temporary whiteness of the skin area), swelling, and itching. There will be the 763 minor discomfort of having the needle/plastic tube taped to the arm. In about one in 10 cases a small
- 764 amount of bleeding under the skin will produce a bruise. The risk of a blood clot forming in the vein
- 765 is about one in 100, while the risk of infection or significant blood loss is one in 1000.
- 766

767 7.5.5 Exercise Risks

- 768 The exercise session during the CRC admission involves exercising for a short time while pulse and 769 blood sugars are monitored. It is routinely used to diagnose heart and lung problems. Four in 770 10,000 people get abnormal heartbeats or chest pain while doing this test. One in 100,000 people 771 die. These are usually older people who have a history of heart conditions.
- 772

773 7.5.6 Risk of Hypoglycemia

- 774 As with any person having insulin-dependent diabetes, there is always a risk of having a low blood 775 sugar (hypoglycemia) and of ketoacidosis. In this study, hypoglycemia may occur during or 776 following the time the exercise portion of the CRC admission. Symptoms of hypoglycemia can 777 include sweating, jitteriness, and not feeling well. Just as at home, there is the possibility of fainting 778 or seizures (convulsions) and that for a few days the subject may not be as aware of symptoms of 779 low blood sugar. Since we will be closely monitoring subjects during the CRC admission, a serious 780 low blood sugar is not expected to occur. Even if severe low blood sugar does occur, it almost 781 always goes away quickly with treatment to raise the blood sugar.
- 782

783 7.5.7 Post-breakfast Hyperglycemia

- 784 The subject's prebreakfast insulin bolus will be held until the completion of the one-hour 785 postbreakfast blood draws. This is expected to produce a greater rise in the blood glucose than 786 would occur had the prebreakfast bolus been given. Hyperglycemia is usually acutely benign, but 787 may be associated with thirst, glycosuria, ketoacidosis, and hyperosmolar coma. A serious effect
- 788 from the hyperglycemia is not expected to occur in a single subject as the insulin bolus will be

- given after an hour and the subjects will be monitored. Because of the monitoring, the risk is lower
- than it would be for the subject at home when a premeal bolus is missed (a not infrequent
- 791 occurrence).
- 792

793 7.5.8 Blood Volume Requirements

At the time of CRC admission, the maximum number of blood draws that can be performed based on a subject's weight will be determined so that the maximum blood volume in the blood draws will

not exceed 5% of the subject's blood volume (calculated by multiplying the subject's weight in

- kilograms by 70 [70cc / kg blood volume] and then multiplying by .05). The maximum number of
- blood draws is then determined by dividing this maximum blood volume by the amount of blood in each blood draw at the center.
- 800

The table below shows the blood volumes for each procedure at the "reinfusion" and "discard" centers, assuming a blood volume of 1.3 ml per blood draw at the "discard" centers and 0.3 ml per blood draw at the "reinfusion" centers. At the "discard" centers, the maximum number of blood

draws per subject will be adjusted if the blood draw amount exceeds 1.3 ml.

- 805
- 806 807

808

809

Table 7.1 Blood Volume Requirements for Study Procedures According to Type of BloodDraw (Reinfusion or Discard)

		Type of Blood Draw Employed at the Clinical Center	
	# of blood	"Reinfusion" "Discard"	
	draws	(0.3 ml per blood draw)	(1.3 ml per blood draw)
Procedure		blood volume (ml)	
A. Half-Hourly measurements for 24 hrs	48	14.4	62.4
B. Quality control samples*	3	0.9	3.9
C. Blood draws for hypoglycemia*	3	0.9	3.9
D. Meal-induced hyperglycemia test	6	1.2	5.2
E. Exercise session	5	1.5	6.5

*This is a maximum number; see section 3.3.2 for details on quality control specimens and section 3.5 for details on
 additional blood draws at times of hypoglycemia

812

813 The tables below indicate the procedures to be done based on the age and/or weight of the subjects.

814 At the reinfusion centers, all procedures will be performed on all subjects with the exception of the 815 exercise, which is only completed for subjects \geq 7 years of age. For discard centers, the procedures

- 816 performed will be based on the age and weight of the subjects.
- 817
- 818

Table 7.2: Procedures to Be Done and Blood Volume Required According to Age of Subject 820

821 A. "Reinfusion" Centers

	Procedure (see description in Table 7.1 for each 'letter')					
Subject Age	Α	В	С	D	Ε	Total Blood Volume*
< 7	14.4	0.9	0.9	1.2	-	17.4
<u>≥</u> 7	14.4	0.9	0.9	1.2	1.5	18.9

822 823 * assumes 0.3 ml per blood draw

824 B. "Discard" Centers

	Procedure					
	(see de	scription i				
Subject Age						Total Blood Volume**
and Weight	Α	В	С	D	E	
<7, 14.5-<20.1 kg	42.9*	3.9	3.9	-	-	50.7
<7, 20.1-21.5 kg	62.4	3.9	3.9	-	-	70.2
<7, ≥21.6 kg	62.4	3.9	3.9	5.2	-	75.4
<u>≥</u> 7, 20.1-21.5 kg	62.4	3.9	3.9	-	-	70.2
<u>≥</u> 7, 21.6-23.3 kg	62.4	3.9	3.9	5.2	-	75.4
<u>≥</u> 7, <u>≥</u> 23.4 kg	62.4	3.9	3.9	5.2	6.5	81.9

825 826 * based on adjusted schedule of every 30 min overnight (9PM – 6AM) and hourly at other times **assumes 1.3 ml per blood draw

827

828 The study may include other risks that are unknown at this time.

829	CHAPTER 8
830	MISCELLANEOUS CONSIDERATIONS
831	
832	8.1 Benefits
833 834	It is expected that continuous glucose monitors will have an important role in the management of diabetes in children. Therefore, the results of this study are likely to be beneficial for children with
835 836	diabetes.
830	It is possible that subjects will not directly benefit from being a part of this study. However, it is
838	
839	also possible that the blood sugar information from the monitor along with the algorithms provided for management decisions will be useful for subjects' diabetes self-management.
840	
841	8.2 Subject/Parent Reimbursement
842 843	The study will provide the Navigator and related supplies, and the Freestyle meter test strips.
844	Children will be paid \$5 for every time the Navigator is downloaded on time and \$2 for every time
845	the Navigator is downloaded late during the first 3 months of the study. The amount earned by the
846	child will be recorded and paid in one payment at the end of the study (Maximum of \$60 during the
847	study).
848	
849	The study will be paying \$100 for the CRC admission and \$25 per completed visit for each of the
850	six required study visits to cover travel and other visit-related expenses. Payment will not be made
851 852	for missed visits. Payment will be made after the child completes the study.
853	8.3 Subject Withdrawal
854	Participation in the study is voluntary, and a subject may withdraw at any time. The investigator
855 856	may withdraw a subject who is not complying with the protocol.
857	8.4 Confidentiality
858	For security purposes, subjects will be assigned an identifier that will be used instead of their name.
859	Protected health information gathered for this study will be shared with the coordinating center, the
860	Jaeb Center for Health Research in Tampa, FL. Information given to the coordinating center will
861	include: diagnosis, general physical exam information (height/weight/blood pressure/etc.) insulin,
862	questionnaire results, hemoglobin A_{1C} results, continuous glucose monitor results, blood work
863	results, HGM blood glucose measurements, information pertaining to hypoglycemic excursions and
864	the treatment given, as well as all other study related data gathered during study visits. During each
865	visit, the study devices will be downloaded to a computer that is secured and password protected,
866	the files will be sent directly to the coordinating center via email. All files will include only the
867	subject's identifier; no names or personal information will be included.
868	
869	The Diabetes Self-Management Profile, administered at baseline and at the 3-month visit, must be
870	conducted via telephone by trained personnel at the Nemours Children's Clinic in Jacksonville, FL.
871 872	If the phone interview cannot be conducted during the office visit, the phone number where the subject and parent can be reached may be provided to the staff at Nemoura. The interview will be
× /)	support and parant can be reached may be provided to the statt of Namours . The interview will be

- subject and parent can be reached may be provided to the staff at Nemours. The interview will be
- 873 conducted at a time that is convenient for the subject and parent.
- 874
- 875 During the study, subjects will be asked to download the Navigator and Freestyle data to their home
- 876 computer. The downloaded data will be emailed to the coordinating center. TheraSense will be
- 877 provided with the downloaded data as well as the data collected for the study during the CRC

admission, at follow-up visits, and during phone contacts. The data provided to TheraSense will include only the subject's identifier; no names or personal information will be included. 878 879

880

881	Chapter 9
882	Statistical Considerations
883	
884	9.1 Sample Size
885	The sample size of 30 for this pilot trial is a convenience sample and is not based on statistical
886	principles.
887	
888	9.2 Analysis Plan
889	The analysis plan is summarized below and will be detailed in a separate document.
890	
891	9.2.1 Assessment of the Feasibility of Using the Navigator Continuous Glucose Sensor on a
892	Daily Basis
893 804	From baseline through 13 weeks, average weekly values will be given for the following:
894	• Number of sensors used
895	Number of sensors unsuccessfully calibrated
896 897	• Hours of sensor use
897 898	Use of the sensor on at least 6 of 7 days will be considered a successful week.
898 899	Use of the sensor of at least 0 of 7 days will be considered a successful week.
900	Results will also be stratified by week. The bootstrap will be used to account for correlated data
901	from the same subject to test whether weekly hours of sensor use remains stable over time. Similar
902	analyses will be conducted to see whether sensor use is associated with subject demographics such
903	as age, gender or weight.
904	
905	9.2.2 Development and Testing of Algorithms for Making Adjustments to Diabetes
906	Management Based on Data from Navigator
907	Downloads from the insulin pump and Freestyle glucose meter will be manually reviewed by study
908	investigators to evaluate the level of subject compliance with the algorithms. Methods for
909	automatically calculating a compliance score based on the expert review will be explored.
910	
911	9.2.3 Questionnaires
912	Analysis of total scores from the PedsQL Diabetes Module and the Diabetes Self-Management
913 014	Profile questionnaires will be analyzed at baseline and 13 weeks separately for patients (≥ 9 years at analyzed). Paired t tests will be used to compare baseline up 12 weeks
914 915	enrollment) and parents (all subjects). Paired t-tests will be used to compare baseline vs. 13-week results separately for patients and parents. Correlations between patient and parent scores and
915 916	baseline and 13-week scores will also be calculated.
917	basefile and 15-week scores will also be calculated.
918	9.2.4 Inpatient Accuracy of the Navigator
919	9.2.4.1 Difference Measures
920	Navigator glucose measurements from the CRC admission will be paired to glucose values from
921	simultaneous blood draws sent to the central laboratory. For each Navigator-reference glucose pair
922	the following accuracy measurements will be calculated:
923	• Difference (Navigator glucose minus reference glucose)
924	• Absolute Difference (absolute value of the Difference)
925	• Relative Difference (Difference divided by reference glucose, expressed as a percentage)
926	• Relative Absolute Difference (absolute value of the Relative Difference)
927	• ISO criteria (binary assessment of accuracy: sensor within $\pm 15 \text{ mg/dL}$ if reference ≤ 75
928	mg/dL or sensor within $\pm 20\%$ if reference > 75 mg/dL)
000	

- 930 The primary assessment of accuracy will exclude glucose values during exercise. Separate analyses
- 931 for exercise are described in Section 9.2.4.5.
- 932
- 933 Mean and 95% confidence interval, median and quartile values will be given for the first four
- accuracy measures listed above as well the percentage of pairs meeting the ISO criteria with 95%confidence interval.
- 936

940

- Median relative absolute difference (RAD) and ISO percentages will be explored in subgroupsdefined by:
 - reference glucose level
 - sensor age
 - day vs. night
- 941 942
- 943 Confidence intervals and statistical comparisons will be done using the bootstrap method to account944 for correlated data from the same subject.
- 945 946 **9.2.4.2 Precision**
- 947 When 2 Navigators are being worn simultaneously during the CRC stay, the glucose values from
- 948 the devices will be paired to each other. The analyses described in Section 9.2.4.1 will be 949 performed for these pairs to describe the precision of the Navigator.
- 950

951 9.2.4.3 Detection of Hypoglycemia

- 952 Hypoglycemic episodes during the CRC stay defined by the reference glucose values will be
- evaluated for Navigator sensitivity (percentage of episodes successfully detected by the Navigator).
 The false alarm rate for Navigator defined episodes of hypoglycemia will also be calculated using
- 954 The rafe and that for Navigator defined episodes of hypogrycenna will also be calculated using 955 the reference glucose data.
- 956
- Analogous calculations of sensitivity and false alarm rates will be calculated for the impendinghypoglycemia alarms.
- 959
- 960 If there are a sufficient number of events, separate analyses will be given for day vs. night. 961
- 962 9.2.4.4 Detection of Hyperglycemia
- Analysis will parallel that described for hypoglycemia in Section 9.2.4.2. The definition of
- hyperglycemia will be $\geq 300 \text{ mg/dL}$.
- 965

966 9.2.4.5 Assessment of Navigator Function during Exercise

- The analyses described in Section 9.2.4.1 will be run separately for Navigator-reference pairs during exercise. The rate error-grid analysis will also be performed separately.
- 969
- 970 Sensitivity rates will also be calculated for hypoglycemia (during exercise). The glycemic
- 971 excursions and rates of change during this period will be compared between reference vs. Navigator
- 972 glucoses by giving summary statistics for the difference, absolute difference, relative difference and
- 973 relative absolute difference.
- 974

975 9.2.4.6 Assessment of Navigator Function Post-Breakfast

- 976 Analysis of the frequent post-breakfast blood draws described in Section 3.7 will include all pairs
- 977 from the start of glucose rise until the reference peak. The start of glucose rise will be defined as
- the first measurement after which the next two values both show a rate of increase ≥ 0.5 mg/dL per

- 979 minute. Sensitivity rates will be calculated for hyperglycemia defined as a reference glucose ≥ 300
- 980 mg/dL. Glycemic excursions and rates of change during this period will be compared between
- 981 reference vs. Navigator glucoses by giving summary statistics for the difference, absolute
- 982 difference, relative difference and relative absolute difference.
- 983

984 9.2.5 Outpatient Accuracy of the Navigator

- 985 Navigator values from home use will be paired with corresponding Freestyle measurements.
- 986 Freestyle values used to calibrate the Navigator will be excluded from analysis. The analyses
- 987 described in Sections 9.2.4.1, 9.2.4.3 and 9.2.4.4 will be repeated for these data to describe
- 988 Navigator accuracy during outpatient use. Additionally, potential associations of accuracy with subject demographics such as age, gender and weight will be explored.
- 989 990

991 9.2.6 Comparison of Subject vs. Staff Freestyle Measurements

- 992 The difference measures described in Section 9.2.3.1 will be computed for the times when the 993 subject and a CRC staff member made simultaneous Freestyle glucose measurements.
- 994

995 9.2.7 Exploratory Assessment of the Effect of Use of the Navigator and Algorithms on A1c 996 and Frequency of Hypoglycemia

- 997 Mean and standard deviation of the A1c values will be given at baseline and 13 weeks. If the 998 distribution of A1c values is suitable for least squares analysis, a paired t-test will be used to 999 compare baseline vs. 13 week values. Otherwise, the Wilcoxon signed-rank test will be used
- 1000 instead. A similar procedure will be used to compare baseline vs. 13 week results for: 1001
 - Number of self-reported weekly episodes of symptomatic hypoglycemia
 - Number of Navigator defined episodes of hypoglycemia •
 - Mean glucose (measured by the Navigator) •
 - Percentage of Navigator measurements in target range 60-180 mg/dL
- 1004 1005

1002

1003

1006 Mean and standard deviation values for the four measures listed above will also be stratified by 1007 baseline A1c values.

1008

1009 9.2.8 Severe Hypoglycemia

1010 All self-reported episodes of severe hypoglycemia defined by seizure or loss of consciousness will 1011 be tabulated.

1012		References
1013		
1014	1.	Boyne, M.S., et al., Timing of changes in interstitial and venous blood glucose measured
1015		with a continuous subcutaneous glucose sensor. Diabetes 52: 2790-2794, 2003.
1016		
1017	2.	Steil, G.M., et al., Accurate determination of plasma glucose during hyper- and
1018		hypoglycemia with a subcutaneous glucose sensor (Abstract). Diabetes 49(Suppl 1): A126,
1019		2000.
1020		